0000899243-21-041467.txt : 20211025
0000899243-21-041467.hdr.sgml : 20211025
20211025182449
ACCESSION NUMBER: 0000899243-21-041467
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211021
FILED AS OF DATE: 20211025
DATE AS OF CHANGE: 20211025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jovan-Embiricos Morana
CENTRAL INDEX KEY: 0001575745
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39409
FILM NUMBER: 211345253
MAIL ADDRESS:
STREET 1: C/O RADIUS HEALTH, INC.
STREET 2: 201 BROADWAY, 6TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allovir, Inc.
CENTRAL INDEX KEY: 0001754068
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 831971007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 433-2605
MAIL ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ViraCyte, Inc.
DATE OF NAME CHANGE: 20180924
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-10-21
0
0001754068
Allovir, Inc.
ALVR
0001575745
Jovan-Embiricos Morana
C/O ALLOVIR, INC.
139 MAIN STREET, SUITE 500
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2021-10-21
4
S
0
85
24.75
D
1399647
I
By F2 MG Limited
Common Stock
2021-10-21
4
S
0
15
24.75
D
346996
I
By F2-TPO Investments, LLC
Common Stock
2021-10-22
4
S
0
4864
24.7697
D
1394783
I
By F2 MG Limited
Common Stock
2021-10-22
4
S
0
859
24.7697
D
346137
I
By F2-TPO Investments, LLC
Common Stock
2021-10-25
4
S
0
6604
24.8183
D
1388179
I
By F2 MG Limited
Common Stock
2021-10-25
4
S
0
1165
24.8183
D
344972
I
By F2-TPO Investments, LLC
Common Stock
411685
I
By F2 MC, LLC
Common Stock
2800000
I
By F2 Capital I 2020 LLC
Common Stock
13420970
I
By ElevateBio LLC
Common Stock
30197
D
These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.
Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.85, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $25.05, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held by F2 MC, LLC ("F2 MC"). Globeways Holdings II Limited is the appointed manager of F2 MC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Shares held by F2 Capital I 2020 LLC ("F2 2020"). Globeways Holdings II Limited is the appointed manager of F2 2020 and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2020. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Shares held by ElevateBio LLC ("ElevateBio"). The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Brett Hagen, as Attorney-in-Fact
2021-10-25